Evidence map›Paper›PMID 33654898›Full record

ArticleBio-protocol2019

Intracerebral Injection of Streptozotocin to Model Alzheimer Disease in Rats.

Daniel Moreira-Silva, Robson C L Vizin, Talita M S Martins, Tatiana L Ferreira, Maria C Almeida, Daniel C Carrettiero

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bio-protocol, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 40 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Vitamin DNeurochemical research · 2026
    Article
  9. Article
  10. Cannabidiol prevents cognitive and social deficits in a male rat model of Alzheimer's disease through CB1 activation and inflammation modulation.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2025
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Daniel Moreira-SilvaGraduate Program in Neuroscience and Cognition, Federal University of ABC, São Bernardo do Campo, Brazil.
Robson C L VizinGraduate Program in Neuroscience and Cognition, Federal University of ABC, São Bernardo do Campo, Brazil.
Talita M S MartinsUndergraduate Program in Neuroscience, Federal University of ABC, São Bernardo do Campo, Brazil.
Tatiana L FerreiraCenter for Mathematics, Computing and Cognition, Federal University of ABC, São Bernardo do Campo, Brazil.
Maria C AlmeidaCenter for Natural and Human Sciences, Federal University of ABC, São Bernardo do Campo, Brazil.
Daniel C CarrettieroCenter for Natural and Human Sciences, Federal University of ABC, São Bernardo do Campo, Brazil.
Universidade Federal do ABC · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Animal models have promoted meaningful contribution to science including Alzheimer's disease (AD) research. Several animal models for AD have been used, most of them related to genetic mutations observed in familial AD. However, sporadic form of AD, also named late-onset is the most frequent form of the disease, which is multifactorial, being influenced by genetic, environmental and lifestyle factors. Here, we describe a protocol of an AD-like pathology of the sporadic form using Wistar rats by a single bilateral intracerebroventricular (icv) injection of streptozotocin (STZ, 2 mg/kg). Icv injection of STZ induces brain resistance to insulin and other pathological alterations related to those observed in AD, such as cognitive impairment and accumulation of phosphorylated tau protein and β-amyloid in the brain. Thus, icv injection of STZ is a useful tool to investigate the pathological mechanisms and the metabolic alterations involved in AD and to propose new therapeutic approaches and neuroprotective drugs.

Indexed as

CognitionGlucoseInsulinMemoryProtocolSTZTauβ-amyloid

Identifiers

PMID33654898
PMCPMC7853929
OpenAlexW2981210585

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.